CVS Quote, Financials, Valuation and Earnings

AngioDynamics has a net margin of 1.88% compared to CVS Health's net margin of -7.55%. CVS Health's return on equity of 7% beat AngioDynamics's return on equity of -17.75%.

CVS Health has a consensus price target of $79.61, signalling upside risk potential of 24.78%. On the other hand AngioDynamics has an analysts' consensus of $19.00 which suggests that it could grow by 120.93%. Given that AngioDynamics has higher upside potential than CVS Health, analysts believe AngioDynamics is more attractive than CVS Health.

CVS Health has a beta of 0.574, which suggesting that the stock is 42.598% less volatile than S&P 500. In comparison AngioDynamics has a beta of 0.602, suggesting its less volatile than the S&P 500 by 39.787%.

CVS Health has a quarterly dividend of $0.67 per share corresponding to a yield of 4.17%. AngioDynamics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CVS Health pays 73.1% of its earnings as a dividend. AngioDynamics pays out -- of its earnings as a dividend. CVS Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CVS Health quarterly revenues are $94.6B, which are larger than AngioDynamics quarterly revenues of $80.2M. CVS Health's net income of $1.8B is higher than AngioDynamics's net income of -$6.1M. Notably, CVS Health's price-to-earnings ratio is 15.23x while AngioDynamics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CVS Health is 0.21x versus 1.20x for AngioDynamics. Usually stocks with elevated PS ratios are considered overvalued.

Humana has a net margin of 1.88% compared to CVS Health's net margin of 3.87%. CVS Health's return on equity of 7% beat Humana's return on equity of 10.08%.

CVS Health has a consensus price target of $79.61, signalling upside risk potential of 24.78%. On the other hand Humana has an analysts' consensus of $291.58 which suggests that it could grow by 28.7%. Given that Humana has higher upside potential than CVS Health, analysts believe Humana is more attractive than CVS Health.

CVS Health has a beta of 0.574, which suggesting that the stock is 42.598% less volatile than S&P 500. In comparison Humana has a beta of 0.441, suggesting its less volatile than the S&P 500 by 55.925%.

CVS Health has a quarterly dividend of $0.67 per share corresponding to a yield of 4.17%. Humana offers a yield of 1.56% to investors and pays a quarterly dividend of $0.89 per share. CVS Health pays 73.1% of its earnings as a dividend. Humana pays out 35.71% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

CVS Health quarterly revenues are $94.6B, which are larger than Humana quarterly revenues of $32.1B. CVS Health's net income of $1.8B is higher than Humana's net income of $1.2B. Notably, CVS Health's price-to-earnings ratio is 15.23x while Humana's PE ratio is 16.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CVS Health is 0.21x versus 0.23x for Humana. Usually stocks with elevated PS ratios are considered overvalued.

IQVIA Holdings has a net margin of 1.88% compared to CVS Health's net margin of 6.5%. CVS Health's return on equity of 7% beat IQVIA Holdings's return on equity of 20.79%.

CVS Health has a consensus price target of $79.61, signalling upside risk potential of 24.78%. On the other hand IQVIA Holdings has an analysts' consensus of $190.67 which suggests that it could grow by 20.19%. Given that CVS Health has higher upside potential than IQVIA Holdings, analysts believe CVS Health is more attractive than IQVIA Holdings.

CVS Health has a beta of 0.574, which suggesting that the stock is 42.598% less volatile than S&P 500. In comparison IQVIA Holdings has a beta of 1.304, suggesting its more volatile than the S&P 500 by 30.422%.

CVS Health has a quarterly dividend of $0.67 per share corresponding to a yield of 4.17%. IQVIA Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CVS Health pays 73.1% of its earnings as a dividend. IQVIA Holdings pays out -- of its earnings as a dividend. CVS Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CVS Health quarterly revenues are $94.6B, which are larger than IQVIA Holdings quarterly revenues of $3.8B. CVS Health's net income of $1.8B is higher than IQVIA Holdings's net income of $249M. Notably, CVS Health's price-to-earnings ratio is 15.23x while IQVIA Holdings's PE ratio is 21.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CVS Health is 0.21x versus 1.86x for IQVIA Holdings. Usually stocks with elevated PS ratios are considered overvalued.

SCWorx has a net margin of 1.88% compared to CVS Health's net margin of -66.13%. CVS Health's return on equity of 7% beat SCWorx's return on equity of -32.77%.

CVS Health has a consensus price target of $79.61, signalling upside risk potential of 24.78%. On the other hand SCWorx has an analysts' consensus of -- which suggests that it could fall by --. Given that CVS Health has higher upside potential than SCWorx, analysts believe CVS Health is more attractive than SCWorx.

CVS Health has a beta of 0.574, which suggesting that the stock is 42.598% less volatile than S&P 500. In comparison SCWorx has a beta of 2.242, suggesting its more volatile than the S&P 500 by 124.167%.

CVS Health has a quarterly dividend of $0.67 per share corresponding to a yield of 4.17%. SCWorx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CVS Health pays 73.1% of its earnings as a dividend. SCWorx pays out -- of its earnings as a dividend. CVS Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CVS Health quarterly revenues are $94.6B, which are larger than SCWorx quarterly revenues of $720.3K. CVS Health's net income of $1.8B is higher than SCWorx's net income of -$476.3K. Notably, CVS Health's price-to-earnings ratio is 15.23x while SCWorx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CVS Health is 0.21x versus 0.24x for SCWorx. Usually stocks with elevated PS ratios are considered overvalued.